SARS-Cov-2 NP IgG/IgM/Abs ELISA kit, CE marked


Clinical Significance
In December 2019, a novel coronavirus, now officially named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified in Wuhan China, which caused the outbreak of a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19). Signs and symptoms of COVID-19 may occur 2 to 14 days after infection, which include fever, cough, shortness of breath or difficulties in breathing, pain in the muscle and tiredness. In severe cases, the infection can further lead to pneumonia, severe acute respiratory syndrome (SARS), kidney failure and death.
Nucleocapsid protein (NP) is the most abundant protein on the helical nucleocapsid of coronaviruses, which envelopes the entire genomic RNA. NP also interacts with other viral structural proteins to play important roles during host cell entry and virus particle assembly and release. Anti-NP antibodies have been shown to be the earliest and the most predominant antibodies detectable in patient’s blood samples after coronavirus infection.

Intended Use
SARS-CoV-2 NP IgG/IgM/Ab ELISA kit is enzyme-linked immunosorbent assay (ELISA) kits for the detection and qualitative measurement of IgG/IgM/Total antibodies against the nucleocapsid protein (NP) of SARS-CoV-2 virus in human blood.
This product is intended for the diagnosis of coronavirus disease 2019 (COVID-19).
This product is intended for use by professional persons only.

Multi-center Validation,
High-Throughput Performance,
Safer to Perform.

Product parameters
Assay Principle
Enzyme-linked immunosorbent assay
Sample Type
Within-run Precision
Interbatch Precision